Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 584-588

  Little, Richard ^a   Wittes, Robert E ^a   Longo, Dan L ^a   Wilson, Wyndham H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VINBLASTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG SAFETY; FEVER; HODGKIN DISEASE; HUMAN; LONG TERM CARE; MALE; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0031892206     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.584     Document Type: Article

References (26)

1. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
2. Nademanee A, O'Donnell MR, Snyder DS, et al: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 5:1381-1390, 1995
3. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle Experience. J Clin Oncol 11:2342-2350, 1993
4. Milpied N, Fielding AK, Pearce RM, et al: Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 14:1291-1296, 1996
5. Klener P, Donner L, Ort J: Use of vinblastine for maintenance therapy in malignant lymphomas. Neoplasma 21:323-329, 1974
6. Carter SK, Livingston RB: Single-agent therapy for Hodgkin's disease. Arch Intern Med 131:377-387, 1973
7. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Hryniuk WM: The importance of dose intensity in the outcome of chemotherapy, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1988, pp 121-141
9. Lohri A, Barnett M, Fairey RN, et al: Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience, 1970 to 1988. Blood 77:2292-2298, 1991
10. Klimo P, Connors JM: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
11. Tannir N, Hagemeister F, Velasquez W, et al: Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 1:432-439, 1983
12. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139-143, 1982
13. Wilson WH, Bryant G, Bates S, et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993
14. Wilson WH, Jain V, Bryant G, et al: Phase I study of vinblastine, ifosfamide and CCNU (VIC) with autologous bone marrow transplantation following cytoreduction for relapsed Hodgkin's disease. Blood 76:2281, 1990 (abstr)
15. Wilson WH, Jain V, Bryant G, et al: Phase I and II study of high-dose ifosfamide, carboplatin and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10:1712-1722, 1992
16. Jagannath S, Dicke KA, Armitage JO, et al: High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104:163-168, 1986
17. Jelliffe AM: Vinblastine in the treatment of Hodgkin's disease. Br J Cancer 23:44-49, 1969
18. Warren RD, Bender RA, Norton L, et al: The treatment of combination chemotherapy-resistant Hodgkin's disease with single-agent vinblastine. Am J Hematol 4:47-55, 1978
19. Flatow FA, Ultmann JE, Hyman GA, et al: Treatment of advanced Hodgkin's disease with vinblastine or procarbazine. Cancer Chemother Rep 53:39-47, 1969
20. Tseng A, Jacobs C, Coleman N, et al: Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide and methotrexate. Cancer Treat Rep 71:475-478, 1987
21. Wilson WH, Bryant G, Wittes R, et al: EPOCH chemotherapy is effective in relapsed and refractory Hodgkin's disease. Pro Am Soc Clin Oncol, 1995 (abstr 1224)
22. Lacher MJ: Vinblastine sulfate in Hodgkin's disease. N Y State J Med 53:808-814, 1969
23. Armstrong JG, Dyke RW, Fouts PJ, et al: Hodgkin's disease, carcinoma of the breast, and other tumor treated with vinblastine sulfate. Cancer Chemother Rep 18:49-56, 1962
24. Frei E III, Luce JK, Gamble JF, et al: Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission. Ann Intern Med 79:376-382, 1973
25. Anderson T, DeVita VT, Young RC: BCNU in the treatment of advanced Hodgkin's disease: Its role in remission induction and maintenance. Cancer Treat Rep 60:761-767, 1976
26. Longo DL, Duffey PL, Young RC, et al: Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease relapsing after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992